Abstract
This review discusses the discovery, development and preliminary investigation of amoxy-cillin-clavulanate (co-amoxiclav), and then details the evidence supporting its prominence in the major areas of clinical usage, concluding with an appraisal of its place in the late 1990s and continued utility beyond the millennium.